With ISIS up over five fold from vicl's total share price in one day the jealous chums don't no what to do. This is the hardest time of the year for stocks in general, and biotech specifically and ISIS has two huge potential winners coming down the track. I've never really been jealous of people so it is difficult for me to understand the way the chums think, including the giant chum. But I do know that the chums will turn to chumps by year-end. t
I am extremely happy. ISIS will be over $75 by year end, RNN will be higher than vicl by that time and the chums will be close to speechless. t
ISIS won't be taken out, the will become one of the biggest companies in the world as far a capitalization is concerned. Just the Korean automakers were fairly unsuccessful at first and later have become world respected so will ISIS. t
Looking forward to RNN's CA presentation on Sept 10th to see vicl in the rear view mirror. ISIS could very well hear about the stopping of their SMA trial early in Type 1 patients as well. t
Down over 5% today. You chums really know a good deal when you see one......t
NO, it really means you are stupid and you don't understand how the market works. The selling of shares rarely means anything. It is the buying of shares that means maybe something positive is going to happen. You chums should all crawl over to the OPK board where the CEO has recently bought some shares. t
The chums were all riding on the Ferris wheel that they purchased about five years ago and it was struck by lightening. Ever since then they can not think in the abstract and one of the chums saw a sign for the gas station Valero and since then they've entranced with anything that starts with the letter "V." Too bad they all seemed to think that the "V" should mean vicl. t
Only three cents separate RNN and VICL. RNN has three exciting cancer drugs, vicl has a drug that lowers viral shedding by 30%(he he he). Before the summer is over RNN should pass up vicl. t
INO, now these guys are kicking little vicl's butt:
Inovio Pharma announces that its DNA vaccine targeting viral MERS induced 100% protection from a live virus challenge in a preclinical study (7.70 +0.28)
In preclinical studies, Inovio and its collaborators evaluated its synthetic DNA-based MERS vaccine in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. The results appear in the peer-reviewed journal Science Translational Medicine in an article entitled, "A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East Respiratory Syndrome Coronavirus in non-human primates."
Not 30% decrease in viral shedding for a not as terrible disease compared to 100% efficacy for MERS. vicl will be going to that big vaccination arm in the sky. t
njknowsnothingchum, I hardly am jealous. All this means is that vicl gets a chance to spend more money that they don't have. Now you chums should be a little bit worried, the stock didn't close up because of this and vicl even if it does have a reverse split that might not keep them out of trouble just like what is happening to MPO:
Midstates Petroleum announces it received notice from the NYSE that its market capitalization and last reported stockholders equity had fallen below the NYSE's continued listing standards (2.87 -0.15)
The NYSE requires that a listed company's total market capitalization not be less than $50 million for a period of over 30 consecutive trading days and that its last reported stockholder equity not be less than $50 million.
Oh-oh, guess you guys didn't maybe realize this. t
Some things to think about in regards to huge potential to the upside. This is kind of a warning to the shorts and the chums. The SMA drug is getting very close I believe to having an early approval based on what we are seeing. The pressure is mounting greatly for its approval based on the fairly amazing things that are happening with these kids. That coupled with the safety of not one child having to be taken off of the med due to any side-effects. Moreover, BIIB with all of their recent problems have become more reliant on ISIS for this drug and the pipeline deal signed with BIIB for over six other targets. A recent analyst noted that if thus drug gets approved that it will almost immediately become BIIB's most important drug. If you look at numbers and how it relates it ISIS let's take a look. First off, the drug will probably be able to gross in five years between $2 and $5 billion. Assume $3 billion, also note that ISIS will receive 15% royalty on REVENUES from that. Say they get about $350 million and give them a P/E of 30, I'll let people jiggly the numbers different ways. My next post if it goes through is extremely powerful and the main reason I would never short ISIS at this juncture. t
You should really switch over to the ALNY board with your same agenda and apply it over there so you can increase your likelihood of being right. They have peeled away their poison pill making a potential buyout easier, they are already 13% owned by SNY, they have had a misstep in their competition with ISIS with their second drug going after TTR-amyloidosis....their sq version, their IV version was always in trouble by having to be given IV and the patients have to receive five different meds before and after the injections....including 24mg of decadron...a potent steroid that may help account for their slightly higher number in lowering TTR-amyloidosis. That small improvement gained by the fairly large dose of decadron will probably be lost by the side-effects of the decadron. Thus ALNY will probably fall another six months behind with that drug and no other drug having the possibility of coming out for probably another 12 to 18 months after that drug. Throw in the mix that ALNY is using about or burning through about $400-$500 million a year in operating expenses, and they have less partnerships than ISIS with ISIS still having a pretty bitter poison pill still place and you have an ALNY set up for a buyout predicted taker.....SNY.
The big thing the chums aren't smart enough to recognize is that some high fliers in wall strret took out hundreds of retail investors by first hamming up the stock to over a buck forty two and then within weeks they hammered it back to below 70 cents a share, and lately lows on the year. Man a lot of technical damage done there. t
1)Will remain snoopy in ISIS business.
2)Will continue to tout the loser stock vicl.
3)Will deny anything bad will happen with vicl.
4)Will suffer through demotion of vicl to the pink sheets, chums will say the stock will be back stronger than ever.
5)When vicl isn't back to NASDQ they will say it doesn't matter.
6)When vicl disappears altogether they will pick a new champion and continue to diss ISIS and remain snoopy and critical, but not really with any real knowledge..
7)In three years the chums will disappear......or it won't matter anymore anyway. t
Some guy looks at some loose variables, probably holds some GILD, worshipping it and yet a bit afraid after the HepC drug kind of runs its course in that it will be competing with itself on a quarter per quarter basis as the wall streeters like to do and someone will announce it has peaked and then you have the run for the door like people are saying what is happening with AAPL. Whether that is true or not the wall streeters will tell the story setting up the little guy for another move based on created fear. t
GILD is kind of a zero company with the $84K per patient charge. If everyone with Hep C in the US alone where to get treated with their drug it would cost $300 billion. They also with that pricing helped to give our congressman something to be self-righteous about in regards to biotech. The price they charge in India is $900 bucks per patient. Companies should be rewarded for their work and they need more for continue R and D but these people really open up wounds with their strategy. t